American Leprosy Missions is committed to bringing an END to leprosy by developing a leprosy vaccine that will stop this terrible disease before it even starts.
So in 2002, American Leprosy Missions began a partnership with the Infectious Disease Research Institute (IDRI) in Seattle, Washington to develop a vaccine for leprosy.
An investment of 15 years and more than $5 million has resulted in a vaccine that has started Phase I clinical safety trials in healthy human volunteers.
This is an exciting opportunity to partner with us to make a lasting difference in the world by opening the door to finally stopping this devastating disease.
Why is a leprosy vaccine needed?
- This ancient disease is still disabling and isolating people.
- Every two minutes someone is diagnosed with leprosy.
- More than four million people in the world suffer from leprosy-related disabilities.
- An effective vaccine will limit infection, prevent disease and reduce transmission.
- A vaccine is the only way to end this terrible disease.
- This is the first leprosy-specific vaccine to go through Phase I clinical trials.
- We believe this vaccine will be an exciting new way to stop the transmission of leprosy and the only way to protect people from the disease long term.
- What’s more, the vaccine may protect against nerve damage, the most serious complication of leprosy.
- The vaccine has received approval from the U.S. Food and Drug Administration.
- This is an historic opportunity to help end an ancient disease.
- With your help, families will never have to hear the devastating news that they have leprosy, nor suffer its debilitating effects.
- You can leave a lasting legacy for millions of people around the world.
Thanks to your generous support, we have raised more than $1.2 million needed for the leprosy vaccine Phase I clinical trial.
This vaccine may be the most exciting breakthrough in leprosy treatment since the cure, multi-drug therapy, was launched in the 1980s. Together we have reached this historic moment. Thank you!
If you’d like to contribute to the leprosy vaccine, we only need $38,158 in order to finish the Phase I clinical trial and another $300,000 to launch Phase II among people most at risk. Donate now.
Progress and next steps
- August 2017: Approved by Food and Drug Administration
- October 2017: Started Phase I clinical trial
- November 2017: Interim safety review successfully completed
- January-March 2018: Complete injections of second cohort; perform last blood draw; begin one-year follow-up period
- June-November 2018: Complete clinical sample processing; analyze data and clinical immunology
- March 2019: Complete Phase I clinical trial
- 2019: Possible start of Phase II clinical trial in an endemic country
Leprosy vaccine in the news
Join us – Together we can help end leprosy
By God’s grace and with your partnership, a vaccine will be able to spare children like Marc Jun the devastation and heartbreak of leprosy. Donate now to stop the suffering.